Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Health economics of chronic infectious diseases: the example of hepatitis C].
Wasem J, Sroczynski G, Aidelsburger P, Buchberger B, Hessel F, Conrads-Frank A, Peters-Blöchinger A, Kurth BM, Wong JB, Rossol S, Siebert U. Wasem J, et al. Among authors: rossol s. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jan;49(1):57-63. doi: 10.1007/s00103-005-1190-7. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006. PMID: 16341606 German.
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, Kurth BM, Bullinger M, von der Schulenburg JM, Wong JB, Rossol S. Siebert U, et al. Among authors: rossol s. Eur J Health Econ. 2005 Jun;6(2):112-23. doi: 10.1007/s10198-005-0280-7. Eur J Health Econ. 2005. PMID: 15902546
Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB. Siebert U, et al. Among authors: rossol s. Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006. Pharmacoeconomics. 2009. PMID: 19485429 Clinical Trial.
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Siebert U, et al. Among authors: rossol s. Gut. 2003 Mar;52(3):425-32. doi: 10.1136/gut.52.3.425. Gut. 2003. PMID: 12584228 Free PMC article. Clinical Trial.
Antiviral treatment initiation costs in chronic hepatitis C.
Siebert U, Wasem J, Rossol S, Sroczynski G, Aidelsburger P, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB. Siebert U, et al. Among authors: rossol s. Gut. 2005 Jan;54(1):172-3. Gut. 2005. PMID: 15591531 Free PMC article. No abstract available.
[Chronic hepatitis C virus infection].
Rossol S, Bartel J. Rossol S, et al. MMW Fortschr Med. 2006 Oct 26;148(43):36-7. doi: 10.1007/BF03364806. MMW Fortschr Med. 2006. PMID: 17619422 German.
111 results